At a glance
ClinicalIndex Comparison RecordPhase 3Active· 80 enrolled
Drug / intervention
combination of Pentoxifylline 400 MG and Folic Acid +2 moredrug
Likely dose
combination of Pentoxifylline 400 MG and Folic Acidfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Potential Nephro-protective Effect of Folic Acid and/or Pentoxifylline on Patients With Chronic Kidney Disease
In Brief
A Phase 3 clinical trial evaluating combination of Pentoxifylline 400 MG and Folic Acid, folic acid, and 1 other intervention for Chronic Kidney Diseases. Active but no longer recruiting, targeting 80 participants across 1 site.
Detailed Summary
The aim of this study is to evaluate the effect of administration of folic acid and /or pentoxifylline on patients with chronic kidney disease (CKD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Kidney Diseases
CountriesEgypt
Collaborators--
Timeline
Phase 3Active
202220232024202520262027
Enrollment StartJan 2022
First PostedMar 2022
Primary CompletionJun 2026
TodayJul 2026
Study CompletionDec 2026
First PostedMar 17, 2022
Enrollment StartJan 8, 2022
Primary CompletionJun 12, 2026
Study CompletionDec 19, 2026
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 4.3 years ago
Interventions
combination of Pentoxifylline 400 MG and Folic Aciddrug
drugs used to delay progression of chronic kidney disease
folic aciddrug
drugs used to delay progression of chronic kidney disease
Pentoxifylline 400 MGdrug
drugs used to delay progression of chronic kidney disease